Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo

Pharmacology. 2019;103(1-2):101-109. doi: 10.1159/000495254. Epub 2018 Dec 6.

Abstract

It has been reported that taxifolin inhibit osteoclastogenesis in RAW264.7 cells. In our research, the inhibition effects of taxifolin on the osteoclastogenesis of human bone marrow-derived macrophages (BMMs) induced by receptor activator of NF-κB ligand (RANKL) as well as the protection effects in lipopolysaccharide-induced bone lysis mouse model have been demonstrated. In vitro, taxifolin inhibited RANKL-induced osteoclast differentiation of human BMMs without cytotoxicity. Moreover, taxifolin significantly suppressed RANKL-induced gene expression, including tartrate-resistant acid phosphatase, matrix metalloproteinase-9 nuclear factor of activated T cells 1 and cathepsin K, and F-actin ring formation. Further studies showed that taxifolin inhibit osteoclastogenesis via the suppression of the NF-κB signaling pathway. In vivo, taxifolin prevented bone loss in mouse calvarial osteolysis model. In conclusion, the results suggested that taxifolin has a therapeutic potential for osteoclastogenesis-related diseases such as osteoporosis, osteolysis, and rheumatoid arthritis.

Keywords: MSC; NF-κB; Osteoclast formation; Osteolysis; Taxifolin.

MeSH terms

  • Actins / metabolism
  • Animals
  • Bone Resorption / chemically induced*
  • Bone Resorption / drug therapy*
  • Cathepsin K / metabolism
  • Cell Differentiation / drug effects
  • Disease Models, Animal
  • Humans
  • I-kappa B Kinase / metabolism
  • Lipopolysaccharides / pharmacology*
  • Macrophages / cytology
  • Macrophages / drug effects*
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • NFATC Transcription Factors / metabolism
  • Osteogenesis / drug effects*
  • Osteolysis / chemically induced
  • Osteolysis / drug therapy
  • Osteolysis / pathology
  • Quercetin / analogs & derivatives*
  • Quercetin / pharmacology
  • RANK Ligand / antagonists & inhibitors*
  • RANK Ligand / pharmacology
  • RAW 264.7 Cells
  • Signal Transduction
  • Transcription Factor RelA / metabolism

Substances

  • Actins
  • Lipopolysaccharides
  • NF-kappa B
  • NFATC Transcription Factors
  • RANK Ligand
  • Transcription Factor RelA
  • Quercetin
  • taxifolin
  • I-kappa B Kinase
  • Cathepsin K
  • Matrix Metalloproteinase 9